Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Hamilton, Canada. In Lancet Oncol, 30 Nov 2014
Patients were stratified according to centre, performance status, tobacco use, best response to previous EGFR tyrosine-kinase inhibitor, weight loss within the previous 3 months, and ethnicity, and were then randomly allocated 2:1 to oral dacomitinib 45 mg once-daily or matched placebo centrally via a web-based system.
Putting together structures of epidermal growth factor receptors.
Philadelphia, United States. In Curr Opin Struct Biol, 24 Nov 2014
UNLABELLED: Numerous crystal structures have been reported for the isolated extracellular region and tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and its relatives, in different states of activation and bound to a variety of inhibitors used in cancer therapy.
Neuregulin 1-activated ERBB4 as a "dedicated" receptor for the Hippo-YAP pathway.
More papers using
Singapore, Singapore. In Sci Signal, Dec 2013
In this issue of Science Signaling, a study by Haskins et al. has brought an end to this scenario of an "orphaned" pathway by identifying neuregulin 1 and its cognate receptor ERBB4 [epidermal growth factor receptor (EGFR) family member v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4] as a major receptor complex that activates YAP activity.
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
In PLoS ONE, 2009
... CA), ER (SP1, prediluted, Ventana Medical Systems, Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, ... Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation.
In PLoS ONE, 2006
... antibody against phospho-IκBα, IκBα, phospho-IKKα/β, IKKα, IKKβ, phospho-p38, p38, phospho-MKK3/6, MKK3, phospho-Akt, Akt, phospho-EGFR and EGFR were purchased from Cell Signaling (MA, USA) ... Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex
In Breast cancer research : BCR, 2003
... used in this study: extracellular signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, total β-catenin, poly(ADP-ribose)polymerase (PARP), EGFR, p-EGFR (tyrosine [Tyr] 845), and p-Tyr-100 (Cell Signaling Technology, Inc., Danvers, MA, ... Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
In PLoS ONE, 2002
... (Abcam, ab654), Glut3 (made in Devaskar's lab, UCLA), Glut1 (Abcam, ab15309), IGFR (Cell Signaling, 111A9), EGFR, (Santacruz, sc 03, 1005), Glucose-6-P dehydrogenase (Abcam, ab34436), Protein Kinase C-zeta ... Can correct protein models be identified?
In Molecular Immunology, 2002
... removed with xylene from sections and immunohistochemistry was performed using the FDA-approved in vitro diagnostic EGFR pharm Dx™ (DAKO, Glostrup, Denmark) and HercepTest ... Protein tyrosine phosphorylation influences adhesive junction assembly and follicular organization of cultured thyroid epithelial cells
In British Journal of Cancer, 1996
... -catenin, and p120 (Transduction Laboratories, California, USA), phosphorylated MARCKS (Cell Signaling, Massachusetts, USA), phosphorylated EGFR (Cell Signaling, Massachusetts, USA), and EGFR ...